UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease

Current clinical pharmacology, 2007-09, Vol.2 (3), p.234

2007

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of Cytosolic Phospholipase A2α: Hit to Lead Optimization

Journal of medicinal chemistry, 2006-01, Vol.49 (1), p.135-158

2006

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, pharmacodynamics, allometry, and dose selection of rPSGL-Ig for phase I trial

The Journal of pharmacology and experimental therapeutics, 2000-05, Vol.293 (2), p.618

2000

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacologic Study of Oral Fluorouracil on a Chronic Daily Schedule in Combination With the Dihydropyrimidine Dehydrogenase Inactivator Eniluracil

Journal of clinical oncology, 2000-02, Vol.18 (4), p.915-926

2000

Link zum Volltext

Verfügbarkeit prüfen

Gel electrophoresis–autoradiographic image analysis of radiolabeled protein drug concentration in serum for pharmacokinetic studies

Journal of pharmacological and toxicological methods, 2002, Vol.47 (1), p.59-66

2002

Link zum Volltext

Verfügbarkeit prüfen

An oxygenation agent and radiation sensitizer, dodecafluoropentane, for the treatment of glioblastoma multiforme

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS2078-TPS2078

2015

Link zum Volltext

Verfügbarkeit prüfen

A modified equilibrium dialysis technique for measuring plasma protein binding : Experimental evaluation with diazepam and nortriptyline

Pharmaceutical research, 1998-10, Vol.15 (10), p.1643-1646

1998

Link zum Volltext

Verfügbarkeit prüfen

Discovery of ecopladib, an indole inhibitor of cytosolic phospholipase A2α

Journal of medicinal chemistry, 2007-03, Vol.50 (6), p.1380-1400

2007

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3202: Imetelstat inhibits telomerase activities in xenograft tumors and bone marrow cells and inhibits tumor growth in xenograft models at plasma exposures equivalent to current clinical exposures in Phase I trials

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.3202-3202

2010

Link zum Volltext

Verfügbarkeit prüfen

Results of a Phase I Study of GRN163L, a Direct Inhibitor of Telomerase, in Patients with Relapsed and Refractory Multiple Myeloma (MM)

Blood, 2008-11, Vol.112 (11), p.3688-3688

2008

Link zum Volltext

Verfügbarkeit prüfen

Area-Based Estimation of the Initial Volume of Distribution and Elimination Rate Constant following Intravenous Bolus Injection

Journal of pharmaceutical sciences, 1991-11, Vol.80 (11), p.1042-1050

1991

Link zum Volltext

Verfügbarkeit prüfen

Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer

Journal of clinical oncology, 1998-04, Vol.16 (4), p.1450-1457

1998

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of cytosolic phospholipase A2alpha: hit to lead optimization

Journal of medicinal chemistry, 2006-01, Vol.49 (1), p.135-158

2006

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of Cytosolic Phospholipase A 2 α: Hit to Lead Optimization

Journal of medicinal chemistry, 2006-01, Vol.49 (1), p.135-158

2006

Link zum Volltext

Verfügbarkeit prüfen

Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans

Cancer chemotherapy and pharmacology, 1996-12, Vol.39 (3), p.233-238

1996

Link zum Volltext

Verfügbarkeit prüfen

Oral delivery of recombinant human interleukin-11 decreases clinical signs and histologic lesions in animal models of inflammatory bowel disease

Gastroenterology (New York, N.Y. 1943), 2000-04, Vol.118 (4), p.A701-A701

2000

Link zum Volltext

Verfügbarkeit prüfen

In vivo absorption properties of orally administered recombinant human interleukin-11

Pharmaceutical research, 2000-04, Vol.17 (4), p.482-485

2000

Link zum Volltext

Verfügbarkeit prüfen

Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. I. Theoretical considerations

Drug metabolism and disposition, 1991-03, Vol.19 (2), p.478

1991

Link zum Volltext

Verfügbarkeit prüfen

Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics : allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans

Cancer chemotherapy and pharmacology, 1997, Vol.39 (3), p.233-238

1997

Link zum Volltext

Verfügbarkeit prüfen

Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. II. Distribution of phencyclidine in the rat

Drug metabolism and disposition, 1991-03, Vol.19 (2), p.486

1991

Link zum Volltext

Verfügbarkeit prüfen

Theoretical and experimental considerations of drug distribution and hepatic uptake and metabolism

Khor, Soo Peang

1989

Link zum Volltext
ProQuest

Fluid shift and protein leakeage corrections in protein binding equilibrium dialysis experiments

International journal of pharmaceutics, 1986, Vol.30 (2-3), p.189-197

1986

Link zum Volltext

Verfügbarkeit prüfen

Fluid shift and protein leakage corrections in protein binding equilibrium dialysis experiments

International journal of pharmaceutics, 1986-06, Vol.30 (2), p.189-197

1986

Link zum Volltext

Verfügbarkeit prüfen

Simultaneous correction for volume shifts and protein leakage in equilibrium dialysis protein binding experiments

International journal of pharmaceutics, 1985, Vol.23 (1), p.109-113

1985

Link zum Volltext

Verfügbarkeit prüfen

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(23)
Dissertationen
(1)

Sprache

Englisch
(24)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Biological And Medical Sciences
(12)
Medical Sciences
(12)
Pharmacology. Drug Treatments
(12)
Humans
(11)
Life Sciences & Biomedicine
(10)
Science & Technology
(10)
Animals
(8)
Pharmacology & Pharmacy
(8)
Rats
(7)
Pharmacokinetics
(6)
Female
(5)
General Pharmacology
(5)
Male
(5)
Pharmacokinetics. Pharmacogenetics. Drug-Receptor Interactions
(5)
Tissue Distribution
(4)
Aged
(3)
Antineoplastic Agents
(3)
Chemotherapy
(3)
Dihydrouracil Dehydrogenase
(3)
Half-Life
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease

Inhibition of Cytosolic Phospholipase A2α: Hit to Lead Optimization

Pharmacokinetics, pharmacodynamics, allometry, and dose selection of rPSGL-Ig for phase I trial

Phase I and Pharmacologic Study of Oral Fluorouracil on a Chronic Daily Schedule in Combination With the Dihydropyrimidine Dehydrogenase Inactivator Eniluracil

Gel electrophoresis–autoradiographic image analysis of radiolabeled protein drug concentration in serum for pharmacokinetic studies

An oxygenation agent and radiation sensitizer, dodecafluoropentane, for the treatment of glioblastoma multiforme

A modified equilibrium dialysis technique for measuring plasma protein binding : Experimental evaluation with diazepam and nortriptyline

Discovery of ecopladib, an indole inhibitor of cytosolic phospholipase A2α

Abstract 3202: Imetelstat inhibits telomerase activities in xenograft tumors and bone marrow cells and inhibits tumor growth in xenograft models at plasma exposures equivalent to current clinical exposures in Phase I trials

Results of a Phase I Study of GRN163L, a Direct Inhibitor of Telomerase, in Patients with Relapsed and Refractory Multiple Myeloma (MM)

Area-Based Estimation of the Initial Volume of Distribution and Elimination Rate Constant following Intravenous Bolus Injection

Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer

Inhibition of cytosolic phospholipase A2alpha: hit to lead optimization

Inhibition of Cytosolic Phospholipase A 2 α: Hit to Lead Optimization

Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans

Oral delivery of recombinant human interleukin-11 decreases clinical signs and histologic lesions in animal models of inflammatory bowel disease

In vivo absorption properties of orally administered recombinant human interleukin-11

Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. I. Theoretical considerations

Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics : allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans

Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. II. Distribution of phencyclidine in the rat

Theoretical and experimental considerations of drug distribution and hepatic uptake and metabolism

Fluid shift and protein leakeage corrections in protein binding equilibrium dialysis experiments

Fluid shift and protein leakage corrections in protein binding equilibrium dialysis experiments

Simultaneous correction for volume shifts and protein leakage in equilibrium dialysis protein binding experiments

Suchergebnisse filtern